Immunovant Inc
IMVT · NASDAQ
Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.
Market Data
Price
$25.72
-0.69 (-2.61%)
Market Cap$5.38B
P/E Ratio—
EPS$—
52W High$29.25
52W Low$12.72
Beta0.68
Data from Finnhub · Updated Mar 11, 2026